Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study-Reference-Cited by-同舟云学术

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study

Published:2022-08 Issue:10351 Volume:400 Page:493-501
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Kuo Kevin H M,Layton D Mark,Lal Ashutosh,Al-Samkari Hanny,Bhatia Joy,Kosinski Penelope A,Tong Bo,Lynch Megan,Uhlig Katrin,Vichinsky Elliott P

Funder

Agios Pharmaceuticals

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. A paradigm shift on beta-thalassaemia treatment: how will we manage this old disease with new therapies?;Cappellini;Blood Rev,2018

2. Thalassaemia;Taher;Lancet,2018

3. Birth prevalence of disorders detectable through newborn screening by race/ethnicity;Feuchtbaum;Genet Med,2012

4. Thalassemia in the emergency department: special considerations for a rare disease;Saliba;Ann Hematol,2020

5. Non-transfusion-dependent thalassaemia: a panoramic survey from pathophysiology to treatment;Bazarbachi;Eur Med J,2016

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRISPR/Cas12a-triggered ordered concatemeric DNA probes signal-on/off multifunctional analytical sensing system for ultrasensitive detection of thalassemia;International Journal of Biological Macromolecules;2024-09

2. Hemolytic anemia due to pyruvate kinase deficiency coexistent with the alpha thalassemia trait and chronic myeloid leukemia;Hematology, Transfusion and Cell Therapy;2024-09

3. Hemoglobin Bart’s hydrops fetalis: charting the past and envisioning the future;Blood;2024-08-22

4. Novel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disorders;Blood;2024-08-22

5. CRISPR technology in human diseases;MedComm;2024-07-29